Licensed cannabis and psilocybin research company focused on advanced research, testing and analysis for the psychedelic-wellness industry Delics Labs has been granted a section 56 exemption from Health Canada giving permission to its researchers to carry out research activities on a number of psychedelics compounds including; 2C-B, DMT, mescaline, MDMA and LSD.
In addition, Delic Labs which is a subsidiary of psychedelic company Delic Holding Corp. (CSE: DELC) (OTCMKTS: DELCF) also received 56 research exemption to acquire 60 grams of psilocybin mushrooms from Nectar Health Sciences Laboratory Division Inc.
The above exemptions will help Delic Labs in developing innovative analytical methods for psychedelic research. The company aims at establishing consistent quality control standards as a growing number of patients and clinicians incorporate psychedelic compounds into treatments plans.
“Securing our latest Health Canada 56 exemptions allow us to advance our research efforts as we continue to understand the medical applications of psychedelic compounds,” said the co-founder of Delic Labs, Dr. Markus Roggen.
In the beginning of last year, the Lab received a section 56 research exemption for psilocybin mushrooms giving it permission to advance extractions methods, analytical testing and chemical development process.
Subsequently, the lab also applied for a dealer’s license in 2021 seeking to commercialize psilocybin research and associated intellectual property for medical and research purposes. Securing this license together with the research exemptions will position Delic Labs as a leader in psychedelic safety testing.
“Psychedelics show tremendous promise as a new class of therapeutics, and Delic Labs is taking extensive measures to establish best practices in developing and manufacturing these potential treatments. We look forward to exploring these novel compounds with the goal of commercializing the research once our dealer’s license is secured,” added Dr. Roggen.
